Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 872

TitleReference numberPublishedLast updated
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Sparsentan for treating primary IgA nephropathyTA1074
Targeted-release budesonide for treating primary IgA nephropathyTA937
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096
Tirzepatide for managing overweight and obesityTA1026
Tirzepatide for treating type 2 diabetesTA924
Guselkumab for treating moderately to severely active ulcerative colitisTA1094
Guselkumab for previously treated moderately to severely active Crohn's diseaseTA1095

Results per page

  1. 10
  2. 25
  3. 50
  4. All